Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6892838 | 0.85 | CTSK (0.36) | CTSKALDH1A1MAPTTSHR | |
| SCHEMBL28169563 | 0.85 | LMNA (0.46) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL12116834 | 0.82 | FAAH (0.51) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL17467181 | 0.82 | FAAH (0.51) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL6894385 | 0.80 | ADORA3 (0.40) | CTSKFAAHALDH1A1MAPTHPGD | |
| SCHEMBL12414955 | 0.78 | MMP1 (0.34) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL6894739 | 0.75 | NR1I2 (0.40) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL6896864 | 0.74 | ALDH1A1 (0.44) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL12116842 | 0.74 | ALDH1A1 (0.44) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL3806654 | 0.74 | EPHX2 (0.41) | ALDH1A1TAS1R3TAS1R1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-9102618-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LTD (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CTSK 4290/4885FAAH 565/4885ALDH1A1 599/4885 |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | CTSK 4290/4885FAAH 565/4885ALDH1A1 599/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | CTSK 2095/4885FAAH 210/4885ALDH1A1 307/4885 |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | CTSK 1006/4885FAAH 203/4885ALDH1A1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.